tirzepatide being pulled Compounded versions of (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said is tirzepatide discontinued 🚨 URGENT:

BPC-157 has been shown to promote angiogenesis by upregulating VEGFR2 and eNOS activity, accelerating the healing of tendon and muscle injuries. Gwyer, D

General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data

Int J Clin Pharmacol Res 10 : 355360 Bidzinska B, Petraglia F, Angioni S, Genazzani AD, Criscuolo M, Ficarra G, Gallinelli A, Trentini GP, Genazzani AR

It should indicate whether each test passed specifications